Oral Answers to Questions

Tania Mathias Excerpts

Wednesday 22nd February 2017 Commons Chamber

[The Prime Minister]

Local authorities have a fund and can exercise discretion. There will be some variation across the country, and steps have been taken to ensure that particularly vulnerable people are not affected in the way that the hon. Gentleman suggests.

[Dr Tania Mathias (Twickenham) (Con)]

Q10. The lack of large-scale vaccine manufacturing has been described as a national security issue for our country, and it will take many years to build that up. Will the Prime Minister look into what more the Government can do to address this highly critical health and defence concern?

[The Prime Minister]

My hon. Friend is absolutely right to raise the issue in that context. The Government take it very seriously. The ability to ensure that we can readily scale up vaccine production in the event of a pandemic is, as she says, vital to our national security. As I am sure she will understand, the precise details are necessarily confidential, but I can assure her that we have provisions in place to ensure that urgently needed vaccines are available in the UK at short notice, including in the event of a pandemic. As an added contingency, we are funding a £10 million competition to establish a world-leading centre for vaccine manufacturing. However, that is only part of the picture, because we are in a strong position: we have one of the most comprehensive and successful vaccination programmes in the world, backed up by £300 million in this year alone.